Financing biotech companies in a post-COVID-19 era
It is undeniable that the COVID-19 crisis has impacted many industries throughout the world, not least the biotech sector.
Join Euronext’s second Biotech Leaders Conference to hear from our panel of experts on the pandemic’s impact on both private and public biotech financing as well as the M&A market. Euronext will also present the findings from our Biotech Barometer H1 2020 and biotech investors survey.
Watch the webinar brought to you by Euronext, KBC Securities, BioWin and Flanders.Bio by clicking the ‘START NOW’ button.
Our media partner for this webinar: Labiotech.eu
Topics covered in the webinar
-
The financing journey of Belgian biotech, argenx
-
Results from Euronext's Biotech Barometer H1 2020
-
Presentation of biotech investor survey
-
Q&A Session
Experts at your service
Benoît van den Hove
Head of Listing at Euronext Brussels
Eric Castaldi
Chief Financial Officer at argenx
Nicolas Meunier
Head of Advisory and IR Solutions at Euronext Corporate Services
Fabienne Van den Keere
Senior Advisor, Life Sciences at Korys
Cédric Moreau
Partner at Sofinnova Partners
Bertrand Grimmonpré
Chief Financial Officer at Miracor Medical
Nathalie Van den Haute
Executive Director Corporate Finance at KBC Securities
About Post-Listing Advisory
Euronext Post-Listing Advisory offers a full range of services and a dedicated team to advise and assist companies in leveraging their listing life:-
Strategic 360° listing diagnostics
-
Equity story review
-
IR action plan
-
Investor targeting
-
Market and listing analytics monitoring
-
Board level reports